FDA sends warning to rogue pharmacies selling Adderall illegally over the internet – Endpoints News

The FDA and DEA are warn­ing pa­tients to toss drugs pur­chased from two un­reg­is­tered phar­ma­cies ac­cused of il­le­gal­ly sell­ing Adder­all on­line.

Kubapharm.com and Pre­mi­um­lightssup­pli­er.com were both ac­cused of sell­ing am­phet­a­mine drugs mar­ket­ed as the AD­HD drug Adder­all with­out a pre­scrip­tion, ac­cord­ing to an FDA state­ment on Tues­day. The agency al­so claims the phar­ma­cies (which failed to reg­is­ter with the DEA) sold the med­ica­tion with­out the prop­er la­bel­ing.

As Adder­all has a high abuse po­ten­tial and “should on­ly be used un­der the su­per­vi­sion of a li­censed health­care pro­fes­sion­al,” the FDA re­quires the med­ica­tion to be sold with a black box warn­ing out­lin­ing the risks.

So far in 2022, the FDA has is­sued six warn­ing let­ters to var­i­ous on­line phar­ma­cies for the un­law­ful sale of drugs over the in­ter­net. How­ev­er, these two warn­ings were specif­i­cal­ly for the sale of Sched­ule II drugs — drugs des­ig­nat­ed by the DEA to have high po­ten­tial for abuse. Adder­all abuse, es­pe­cial­ly among stu­dents and young adults, has been a wide­spread is­sue for the past two decades.

As a re­sult of the Covid-19 pan­dem­ic, on­line phar­ma­cies grew sub­stan­tial­ly, and rogue phar­ma­cies fol­lowed. These il­le­git­i­mate phar­ma­cies ex­ploit­ed cus­tomers by sell­ing pur­port­ed Covid-19 treat­ments among oth­er med­ica­tions.

Out­side of Adder­all, both sites claim to sell var­i­ous oth­er drugs, in­clud­ing anx­i­ety med­ica­tion Xanax. Con­sumers should toss any med­ica­tions pur­chased from these sites, the FDA said.

“The il­le­gal sale of pre­scrip­tion drug stim­u­lants on­line puts Amer­i­cans at risk and con­tributes to po­ten­tial abuse, mis­use and over­dose,” FDA Com­mis­sion­er Robert Califf said in the press re­lease. “These par­tic­u­lar types of on­line phar­ma­cies al­so un­der­mine our ef­forts to help con­sumers safe­ly pur­chase le­git­i­mate pre­scrip­tion med­i­cines over the in­ter­net.”

The let­ters were is­sued on March 30, and ac­cord­ing to the FDA, the web­sites will have 15 days to re­spond with spe­cif­ic steps for ad­dress­ing their vi­o­la­tions.


Source link

Leave a Reply